DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Treatment of Childhood Acute Lymphoblastic Leukemia

Phase 3

Terminated

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 491

Registration Number: NCT00165087

Locations: 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇺🇸
Maine Medical Center, Lewiston, Maine, United States

and more 7 locations

Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer

Not Applicable

Completed

Conditions: Malignant Tumors
Subcutaneous Tumors
Lymph Node Tumors

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00165100

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma

Phase 2

Completed

Conditions: Colorectal Adenocarcinoma

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00165217

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma

Not Applicable

Terminated

Conditions: Breast Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00165581

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT00165334

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma
Gliosarcoma
Malignant Gliomas

First Posted Date: 2005-09-14

Last Posted Date: 2010-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00165477

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: doxorubicin
Drug: prednisone
Drug: dexamethasone
Drug: E. coli asparaginase
Drug: vincristine
Drug: methotrexate
Drug: Leucovorin
Drug: cytarabine
Drug: Asparaginase
Drug: Methotrexate/Hydrocortisone

First Posted Date: 2005-09-14

Last Posted Date: 2013-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 498

Registration Number: NCT00165178

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

Not Applicable

Active, not recruiting

Conditions: Hodgkin's Disease

Interventions: Procedure: Echo/Stress Echo

First Posted Date: 2005-09-14

Last Posted Date: 2024-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 210

Registration Number: NCT00165425

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease

Completed

Conditions: Breast Cancer
Hodgkin's Disease

First Posted Date: 2005-09-14

Last Posted Date: 2019-05-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 148

Registration Number: NCT00165412

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A-protein Levels in Adult and Pediatric Brain Tumor Patients

Completed

Conditions: Malignant Childhood Central Nervous System Neoplasm

Interventions: Other: A PROTEIN level

First Posted Date: 2005-09-14

Last Posted Date: 2016-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00165542

Locations: 🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy